Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

201 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Correlation of hypertension and proteinuria with outcome in elderly bevacizumab-treated patients with metastatic colorectal cancer.
Feliu J, Salud A, Safont MJ, García-Girón C, Aparicio J, Losa F, Bosch C, Escudero P, Casado E, Jorge M, Bohn U, Pérez-Carrión R, Carmona A, Custodio AB, Maurel J. Feliu J, et al. Among authors: escudero p. PLoS One. 2015 Jan 20;10(1):e0116527. doi: 10.1371/journal.pone.0116527. eCollection 2015. PLoS One. 2015. PMID: 25602286 Free PMC article.
Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer.
Feliu J, Safont MJ, Salud A, Losa F, García-Girón C, Bosch C, Escudero P, López R, Madroñal C, Bolaños M, Gil M, Llombart A, Castro-Carpeño J, González-Barón M. Feliu J, et al. Among authors: escudero p. Br J Cancer. 2010 May 11;102(10):1468-73. doi: 10.1038/sj.bjc.6605663. Epub 2010 Apr 27. Br J Cancer. 2010. PMID: 20424611 Free PMC article. Clinical Trial.
First-line bevacizumab and capecitabine-oxaliplatin in elderly patients with mCRC: GEMCAD phase II BECOX study.
Feliu J, Salud A, Safont MJ, García-Girón C, Aparicio J, Vera R, Serra O, Casado E, Jorge M, Escudero P, Bosch C, Bohn U, Pérez-Carrión R, Carmona A, Martínez-Marín V, Maurel J. Feliu J, et al. Among authors: escudero p. Br J Cancer. 2014 Jul 15;111(2):241-8. doi: 10.1038/bjc.2014.346. Epub 2014 Jun 19. Br J Cancer. 2014. PMID: 24946000 Free PMC article. Clinical Trial.
Dynamic soluble changes in sVEGFR1, HGF, and VEGF promote chemotherapy and bevacizumab resistance: A prospective translational study in the BECOX (GEMCAD 09-01) trial.
Pineda E, Salud A, Vila-Navarro E, Safont MJ, Llorente B, Aparicio J, Vera R, Escudero P, Casado E, Bosch C, Bohn U, Pérez-Carrión R, Carmona A, Ayuso JR, Ripollés T, Bouzas R, Gironella M, García-Albéniz X, Feliu J, Maurel J. Pineda E, et al. Among authors: escudero p. Tumour Biol. 2017 Jun;39(6):1010428317705509. doi: 10.1177/1010428317705509. Tumour Biol. 2017. PMID: 28621236 Free article. Clinical Trial.
First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study.
Díaz-Rubio E, Gómez-España A, Massutí B, Sastre J, Abad A, Valladares M, Rivera F, Safont MJ, Martínez de Prado P, Gallén M, González E, Marcuello E, Benavides M, Fernández-Martos C, Losa F, Escudero P, Arrivi A, Cervantes A, Dueñas R, López-Ladrón A, Lacasta A, Llanos M, Tabernero JM, Antón A, Aranda E; Spanish Cooperative Group for the Treatment of Digestive Tumors. Díaz-Rubio E, et al. Among authors: escudero p. Oncologist. 2012;17(1):15-25. doi: 10.1634/theoncologist.2011-0249. Epub 2012 Jan 10. Oncologist. 2012. PMID: 22234633 Free PMC article. Clinical Trial.
Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer.
Codony-Servat J, Cuatrecasas M, Asensio E, Montironi C, Martínez-Cardús A, Marín-Aguilera M, Horndler C, Martínez-Balibrea E, Rubini M, Jares P, Reig O, Victoria I, Gaba L, Martín-Richard M, Alonso V, Escudero P, Fernández-Martos C, Feliu J, Méndez JC, Méndez M, Gallego J, Salud A, Rojo F, Castells A, Prat A, Rosell R, García-Albéniz X, Camps J, Maurel J. Codony-Servat J, et al. Among authors: escudero p. Br J Cancer. 2017 Dec 5;117(12):1777-1786. doi: 10.1038/bjc.2017.279. Epub 2017 Nov 9. Br J Cancer. 2017. PMID: 29123263 Free PMC article.
Prospective Biomarker Study in Advanced RAS Wild-Type Colorectal Cancer: POSIBA Trial (GEMCAD 10-02).
García-Albéniz X, Alonso V, Escudero P, Méndez M, Gallego J, Rodríguez JR, Salud A, Fernández-Plana J, Manzano H, Zanui M, Falcó E, Feliu J, Gil M, Fernández-Martos C, Bohn U, Alonso C, Calderero V, Rojo F, Cuatrecasas M, Maurel J. García-Albéniz X, et al. Among authors: escudero p. Oncologist. 2019 Nov;24(11):e1115-e1122. doi: 10.1634/theoncologist.2018-0728. Epub 2019 Jun 24. Oncologist. 2019. PMID: 31235483 Free PMC article. Clinical Trial.
Phase II randomized trial of capecitabine with bevacizumab and external beam radiation therapy as preoperative treatment for patients with resectable locally advanced rectal adenocarcinoma: long term results.
Salazar R, Capdevila J, Manzano JL, Pericay C, Martínez-Villacampa M, López C, Losa F, Safont MJ, Gómez-España A, Alonso-Orduña V, Escudero P, Gallego J, García-Paredes B, Palacios A, Biondo S, Grávalos C, Aranda E; Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD). Salazar R, et al. Among authors: escudero p. BMC Cancer. 2020 Nov 27;20(1):1164. doi: 10.1186/s12885-020-07661-z. BMC Cancer. 2020. PMID: 33246428 Free PMC article. Clinical Trial.
Raltitrexed in the treatment of elderly patients with advanced colorectal cancer: an active and low toxicity regimen.
Feliu J, Mel JR, Camps C, Escudero P, Aparicio J, Menéndez D, García Girón C, Rodriguez MR, Sánchez JJ, González Barón M; Oncopaz Cooperative Group Associated Hospitals. Feliu J, et al. Among authors: escudero p. Eur J Cancer. 2002 Jun;38(9):1204-11. doi: 10.1016/s0959-8049(02)00005-9. Eur J Cancer. 2002. PMID: 12044507 Clinical Trial.
201 results